Evidence map›Paper›PMID 31316912›Full record

ArticleFrontiers in oncology2019

Offsetting Expression Profiles of Prognostic Markers in Prostate Tumor vs. Its Microenvironment.

Zhenyu Jia, Jianguo Zhu, Yangjia Zhuo, Ruidong Li, Han Qu, Shibo Wang, Meiyue Wang, Jianming Lu, John M Chater, Renyuan Ma and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 2 countries.

Zhenyu JiaDepartment of Botany and Plant Sciences, University of California, Riverside, Riverside, CA, United States.
Jianguo ZhuDepartment of Urology, Guizhou Provincial People's Hospital, Guangzhou, China.
Yangjia ZhuoDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Ruidong LiDepartment of Botany and Plant Sciences, University of California, Riverside, Riverside, CA, United States.
Han QuDepartment of Botany and Plant Sciences, University of California, Riverside, Riverside, CA, United States.
Shibo WangDepartment of Botany and Plant Sciences, University of California, Riverside, Riverside, CA, United States.
Meiyue WangDepartment of Botany and Plant Sciences, University of California, Riverside, Riverside, CA, United States.
Jianming LuDepartment of Botany and Plant Sciences, University of California, Riverside, Riverside, CA, United States.
John M ChaterDepartment of Botany and Plant Sciences, University of California, Riverside, Riverside, CA, United States.
Renyuan MaDepartment of Botany and Plant Sciences, University of California, Riverside, Riverside, CA, United States.
Ze-Zhen LiuDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Zhiduan CaiDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Yongding WuDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Funeng JiangDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Huichan HeDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Wei-De ZhongDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Chin-Lee WuDepartment of Pathology and Urology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
University of California, Riverside · USGuangzhou Medical University · CNSouth China University of Technology · CNGuangzhou First People's Hospital · CNGuizhou Provincial People's Hospital · CNMassachusetts General Hospital · US

Funding

Acquisition of a Scalable Storage Cluster for Data Intensive NIH ResearchS10OD016290 · OD · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI GIRKE, THOMAS · 2014 to 2014
$593k
NIH HHS S10 OD016290
6 · The paper itself

Abstract

Diagnosis of the presence of tumors and subsequent prognosis based on tumor microenvironment becomes more clinically practical because tumor-adjacent tissues are easy to collect and they are more genetically homogeneous. The purpose of this study was to identify new prognostic markers in prostate stroma that are near the tumor. We have demonstrated the prognostic features of FGFR1, FRS2, S6K1, LDHB, MYPT1, and P-LDHA in prostate tumors using tissue microarrays (TMAs) which consist of 241 patient samples from Massachusetts General Hospital (MGH). In this study, we investigated these six markers in the tumor microenvironment using an Aperio Imagescope system in the same TMAs. The joint prognostic power of markers was further evaluated and classified using a new algorithm named Weighted Dichotomizing. The classifier was verified via rigorous 10-fold cross validation. Statistical analysis of the protein expression indicated that in tumor-adjacent stroma FGFR1 and MYPT1 were significantly correlated with patient outcomes and LDHB showed the outcome-association tendency. More interestingly, these correlations were completely opposite regarding tumor tissue as previously reported. The results suggest that prognostic testing should utilize either tumor-enriched tissue or stroma with distinct signature profiles rather than using mixture of both tissue types. The new classifier based on stroma tissue has potential value in the clinical management of prostate cancer patients.

Indexed as

biochemical recurrencemicroenvironmentoffsetting expressionprognosisprostate cancertissue microarray

Identifiers

PMID31316912
PMCPMC6611437
OpenAlexW2955197113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.